Ruboxistaurin
（重定向自Arxxant）
![](/Images/godic/202412/22/Ruboxistaurin.svg0038.png")
![Ball-and-stick model of the ruboxistaurin molecule](/Images/godic/202412/22/Ruboxistaurin_3D_ball0038.png")
Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic peripheral retinopathy being investigated by Eli Lilly and Company. It is a member of the bisindolylmaleimide family.
On February 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an "approvable" letter from the United States Food and Drug Administration for ruboxistaurin, with a request for an additional clinical trial, which would take 5 years to complete.